News | EP Lab | September 27, 2016

European Heart Rhythm Association Releases EHRA White Book 2016 EP Europace Supplement

Annual supplement provides in-depth analysis on increasing atrial fibrillation ablations and CRT use; highlights continued inequalities in ICD therapy across Europe

European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe

September 27, 2016 — In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement to its ninth annual EHRA White Book, developed in partnership with Biotronik. The supplement was released just ahead of the 2016 European Society of Cardiology (ESC) Congress, Aug. 27-31 in Rome.

The 2016 EP Europace Supplement provides deeper analysis into data presented in the ninth annual EHRA White Book, which collects and distributes information on the yearly number of cardiac rhythm device implantations and catheter ablations in 50 of the 56 ESC member countries. Consistent with the findings of previous editions, the EHRA White Book 2016 found persistent inequalities across ESC countries in access to treatment for cardiac arrhythmias. It found many ESC countries, particularly in eastern Europe and those not on the European continent, fall behind western European countries in the use of implantable cardioverter defibrillators (ICDs) in a number of key arrhythmia treatments.

“Having this data helps us assess how well we’re able to treat groups of patients who may have been underserved in the past,” said 2016 EHRA White Book Coordinator Pekka Raatikainen, M.D., Finland. “We still need to address the disparities between countries in terms of access to all arrhythmia treatments, whether the issues have to do with finances, facilities, manpower or training. One of EHRA’s key goals is to reduce this gap in a number of ways, particularly through training and fellowships.”

The EHRA White Book 2016 also found an increase in the number of ablations for atrial fibrillation and ventricular tachycardia, as well as an increase in cardiac resynchronization therapy (CRT) and the use of insertable cardiac monitors (ICMs), among other findings. “It is particularly encouraging to see evidence that the number of ablations for atrial fibrillation continues to increase,” commented 2016 EHRA White Book Co-coordinator David O. Arnar, M.D., Iceland. “In combination with increasing ICM use, also documented in the EHRA White Book, we can not only treat patients, but monitor them continuously post-ablation to better gauge success rates.”

Biotronik has supported the EHRA White Book through an unrestricted educational grant since the first edition in 2008.

For more information: www.escardio.org


Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now